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Inflammatory processes are important in the pathogenesis of Alzheimer’s disease and in response to amyloid-b immunotherapy.
We investigated the expression of multiple inflammatory markers in the brains of 28 non-immunized patients with Alzheimer’s
disease and 11 patients with Alzheimer’s disease immunized against amyloid-b42 (AN1792): microglial ionized calcium-binding
adaptor Iba-1, lysosome marker CD68, macrophage scavenger receptor A, Fc receptors I (CD64) and II (CD32); and also
immunoglobulin IgG, complement C1q and the T lymphocyte marker CD3 using immunohistochemistry. The data were analysed
with regard to amyloid-b and phospho-tau pathology, severity of cerebral amyloid angiopathy and cortical microhaemorrhages. In
non-immunized Alzheimer’s disease cases, amyloid-b42 correlated inversely with CD32 and Iba-1, whereas phospho-tau correlated
directly with all microglial markers, IgG, C1q and the number of T cells. In immunized Alzheimer’s disease cases, amyloid-b42 load
correlated directly with macrophage scavenger receptor A-positive clusters and inversely with C1q. The severity of cerebral
amyloid angiopathy and microhaemorrhages did not relate to any of the analysed markers. Overall, the levels of CD68, macro-
phage scavenger receptor A, CD64, CD32 and the number of macrophage scavenger receptor A-positive plaque-related clusters
were significantly lower in immunized than non-immunized cases, although there was no significant difference in Iba-1 load,
number of Iba-1-positive cells, IgG load, C1q load or number of T cells. Our findings indicate that different microglial populations
co-exist in the Alzheimer’s disease brain, and that the local inflammatory status within the grey matter is importantly linked with
tau pathology. After amyloid-b immunization, the microglial functional state is altered in association with reduced amyloid-b and
tau pathology. The results suggest that, in the long term, amyloid-b immunotherapy results in downregulation of microglial
activation and potentially reduces the inflammation-mediated component of the neurodegeneration of Alzheimer’s disease.
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Introduction
Alzheimer’s disease accounts for 460% of all dementia cases
(Albanese et al., 2007). The disease is characterized by the pres-
ence of cortical extracellular plaques of amyloid-b protein and
intraneuronal phospho-tau protein aggregates (Lowe et al.,
2008). Both amyloid-b and tau have been hypothesized as initi-
ators of the tissue damage in Alzheimer’s disease (Gray et al.,
1987; Hardy and Higgins, 1992). Neuroinflammation, manifested
by activation of microglia, is an important component of
Alzheimer’s disease pathology with evidence to suggest that it is
both a reaction to the disease process and a contributor to the
neuronal damage (Akiyama et al., 2000; Perry et al., 2010; Zotova
et al., 2010). Recent genetic studies provide further evidence that
inflammatory processes are important in the pathogenesis of
Alzheimer’s disease (Harold et al., 2009; Lambert et al., 2009;
Guerreiro et al., 2013; Jonsson et al., 2013).
Microglial cells play a key role in the innate immune system re-
sponse within the CNS. In Alzheimer’s disease, microglia have been
implicated in the generation of chronic low-grade neurotoxic inflam-
mation around amyloid-b plaques, while being unable to clear them
effectively (McGeer et al., 1987; Rogers et al., 1988; Griffin et al.,
1989; Rozemuller et al., 1989; Mattiace et al., 1990; Paresce et al.,
1997; Overmyer et al., 1999). In vivo imaging of microglia (by use of
PK11195-PET) and fibrillar amyloid (Pittsburgh compound B-PET)
show higher levels of both markers in the cortex in patients with
Alzheimer’s disease compared with non-demented control subjects
(Cagnin et al., 2001; Edison et al., 2007, 2008). Increasing microglial
activation correlates with progression of cognitive decline without
further changes in the amyloid load (Edison et al., 2008). Although
the exact functional state of the microglia is not clear from these
studies, they support a role for persistent neuroinflammation in dis-
ease progression.
Based on the amyloid cascade hypothesis, suggesting that amyl-
oid-b accumulation is the trigger for Alzheimer’s disease pathogen-
esis (Hardy and Higgins, 1992), active immunization against amyloid-
b42 peptide was proposed as a treatment. This approach was shown
to result in the removal of amyloid plaques from the brains of human
amyloid-b precursor protein (APP) transgenic mice (Schenk et al.,
1999; Bard et al., 2000; Janus et al., 2000; Morgan et al., 2000),
and the plaque clearance was associated with behavioural improve-
ments (Janus et al., 2000; Morgan et al., 2000; Dodart et al., 2002).
Microglial activity was implicated in this effect (Bard et al., 2000;
Wilcock et al., 2001, 2003, 2004a, b). In the active amyloid-b42 im-
munization clinical trial that followed (Elan Pharmaceuticals,
AN1792), most aspects of cognitive change did not differ signifi-
cantly between immunized patients and control subjects (Hock
et al., 2003; Bayer et al., 2005; Gilman et al., 2005), with longer
term clinical follow-up revealing continuing cognitive decline despite
removal of plaques (Holmes et al., 2008). In addition, the develop-
ment of side-effects including ‘meningoencephalitis’ with infiltration
by T lymphocytes, and ‘amyloid-related imaging abnormalities’,
associated with cerebral amyloid angiopathy and cortical microhae-
morrhages in a proportion of patients with Alzheimer’s disease immu-
nized against amyloid-b has been problematic (Nicoll et al., 2003;
Orgogozo et al., 2003; Boche et al., 2008; Sperling et al., 2011).
In this study, we explored in detail the inflammatory processes
in the brain in Alzheimer’s disease and compared the results with
those in patients with Alzheimer’s disease following active amyl-
oid-b42 immunization (Elan Pharmaceuticals, AN1792). We
assessed the microglial load by quantifying immunostaining for
ionized calcium-binding adaptor molecule 1 (Iba-1), which has
been reported to be an effective marker of both resting and acti-
vated microglia (Imai et al., 1996; Ahmed et al., 2007; Streit
et al., 2009). In an attempt to define not only their activation
level but also their functional status, we have investigated the
expression of macrophage scavenger receptor-A (MSR-A) involved
in microglial endocytosis of extracellular material, including fibrillar
amyloid-b (El Khoury et al., 1996; Chung et al., 2001), the micro-
glial lysosomal protein CD68 as an indicator of phagocytic activity
(Rabinowitz and Gordon, 1989, 1991; Zotova et al., 2011), and
the microglial cell surface receptors that bind IgG and immune
complexes (Fc receptors I and II) (Ravetch and Bolland, 2001;
Nimmerjahn and Ravetch, 2006). The level of C1q was assessed to
investigate the role of the complement system in relation to
Alzheimer’s disease pathology, microglial activation, and immun-
ization status (Eikelenboom and Veerhuis, 1996). As we previously
found that anti-amyloid-b IgG persisted in the blood of immunized
patients with Alzheimer’s disease for many years (Holmes et al.,
2008), we also investigated whether there were changes in the
overall amount of IgG antibody in the brain. T lymphocytes were
previously identified in some immunized patients with Alzheimer’s
disease (Nicoll et al., 2003; Orgogozo et al., 2003; Ferrer et al.,
2004) and were also analysed. We explored the relationships of
these inflammatory markers to amyloid-b and phospho-tau load,
the severity of cerebral amyloid angiopathy and cortical
microhaemorrhages.
Materials and methods
Immunized Alzheimer’s disease cases
We performed a follow-up study of patients who were enrolled in the
Phase I Elan Pharmaceuticals Inc. active amyloid-b42 immunization
(AN1792) clinical trial for Alzheimer’s disease (Bayer et al., 2005;
Holmes et al., 2008). As part of the study, participants were invited
to consent to post-mortem neuropathology. The study received ethical
approval from Southampton and South West Hampshire Local
Research Ethics Committees (Reference No: LRC 075/03/w). In the
study reported here, we investigated brain tissue from 11 patients who
took part in the clinical trial and had confirmation of the diagnosis of
Alzheimer’s disease by post-mortem neuropathology (Table 1).
Neurodegenerative pathology was assessed by standard methods
including analysis of paraffin sections stained with haematoxylin and
eosin, Luxol fast blue/Cresyl violet, and modified Bielschowsky silver
impregnation, and immunostained for amyloid-b, tau, -synuclein and
TAR-DNA binding protein 43 (TDP43). All immunized Alzheimer’s dis-
ease cases were Braak stage V/VI, indicating an advanced stage of
Alzheimer’s tau pathology (Table 1). Two of the 11 cases had con-
comitant Lewy body pathology (one neocortical and nigral, one nigral
only). No TDP43 inclusions and no argyrophilic grains were identified.
In terms of cerebrovascular disease, none had macroscopic infarcts;
one had an old frontal cortical haemorrhage (2-cm diameter);
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all had varying degrees of arteriolosclerosis, most marked in the cere-
bral white matter where it was moderate or severe.
Non-immunized Alzheimer’s disease
controls
Post-mortem material from sufficient numbers of placebo patients in
the immunotherapy trial was not available, therefore paraffin sections
from 28 cases with Alzheimer’s disease from the South-West
Dementia Brain Bank (Frenchay Hospital, Bristol, UK) were used as
non-immunized controls (Table 1) (Research ethics committee refer-
ence: 08/H0106/28). All control Alzheimer’s disease cases had a clin-
ical diagnosis of dementia made during life by an experienced clinician,
a Mini-Mental State Examination score of 517 before death and
satisfied post-mortem neuropathological Consensus Criteria for
Alzheimer’s disease (Hyman and Trojanowski, 1997). The immunized
and control Alzheimer’s disease cases were matched as closely as pos-
sible for age, gender, duration of dementia and APOE genotype.
The most common causes of death cited from all listed causes, in
addition to dementia, were bronchopneumonia (immunized
Alzheimer’s disease, 27%; non-immunized controls, 46%), myocardial
infarction (immunized Alzheimer’s disease, 9%; non-immunized con-
trols 7%) and cerebrovascular accident (non-immunized controls, 7%).
Other causes of death included: immunized Alzheimer’s disease—a
ruptured aortic aneurysm, pulmonary embolism; non-immunized con-
trols—pyelonephritis, sigmoid volvulus. One immunized Alzheimer’s
disease case and six non-immunized control cases have unknown
cause of death.
Immunohistochemistry
For the purposes of this study, the following regions of cerebral cortex
usually markedly affected by the Alzheimer’s disease process were
used: superior and middle temporal gyrus, medial frontal gyrus and
inferior parietal lobule. Four micrometre-thick sections of formalin-
fixed paraffin-embedded tissue from these areas were used for
immunohistochemistry.
Primary antibodies
Sections were immunostained with the following antibodies: mouse
anti-human specific for amyloid-b42 (clone 21F12) provided by Elan
Pharmaceuticals Inc. (Johnson-Wood et al., 1997); mouse anti-human
phospho-tau (clone AT8, Autogen Bioclear); mouse anti-human CD68
(Dako); goat anti-human CD64 (Fc receptor I), goat anti-human
CD32 (Fc receptor II), goat anti-human MSR-A (all from R&D
Systems); rabbit anti-human Iba-1 (Wako Laboratories); rabbit anti-
human IgG (Dako); rabbit anti-human C1q (Dako); mouse anti-
human CD3 (Abcam). Table 2 specifies the functions associated with
each of the microglial markers.
Immunohistochemistry
Sections from immunized Alzheimer’s disease and non-immunized
control cases were immunostained together in batches for each anti-
body to ensure comparability of labelling. Immunohistochemistry was
performed using the appropriate antigen retrieval methods for each
primary antibody. Biotinylated secondary antibodies (rabbit anti-
mouse, swine anti-rabbit, and rabbit anti-goat) were from Dako,
normal serum and avidin–biotin complex were from Vector
Laboratories. Bound antibody was visualized using the avidin–biotin-
peroxidase complex method (Vectastain Elite ABC) with 3,3’ diamino-
benzidine as chromogen and 0.05% hydrogen peroxide as substrate to
produce a brown reaction product. All sections were dehydrated
before mounting in DePeX (BDH Laboratory Supplies). Sections incu-
bated in the absence of the primary antibody were included as
negative controls.
Quantification
All quantification was performed blind to the experimental group and
identity of the cases. Images of the slides were taken from the same
anatomical regions in every case. For a given antibody, a minimum of
20 fields of cortical grey matter at magnification 10 (for amyloid-
b42, CD64, CD32, Iba-1, MSR-A, and IgG) or 30 fields of cortical
grey matter at magnification 20 (for AT8 and CD68) that covered
a similar area, were analysed to ensure representative detection of
immunostaining for image analysis. Images were acquired in a
Table 1 Clinical characteristics of immunized Alzheimer’s disease (iAD) and non-immunized (control) Alzheimer’s disease
(cAD) subjects
ID Gender Age Braak stage Dementia
duration
(years)
APOE
genotype
Mean antibody
response
(ELISA units)
Survival time from
first immunization
dose (months)
iAD1 F 74 VI 6 3.4 1:119 20
iAD2 M 83 V 11 3.3 51:100 4
iAD3 M 63 VI 6 3.3 51:100 41
iAD4 F 71 VI 10 3.3 1:4072 44
iAD5 M 81 VI 7 3.4 1:1707 57
iAD6 M 82 VI 6 3.4 1:4374 60
iAD7 M 63 VI 10 3.4 1:6470 64
iAD8 M 81 VI 11 4.4 1:491 63
iAD9 F 88 VI 11 3.3 1:137 86
iAD10 M 88 VI 12 3.4 1:142 94
iAD11 F 89 VI 15 3.4 1:142 111
cAD (n = 28) 15F:13M 63–88 V/VI 3–17 21"4 + : 6 "4 – –
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zigzag sequence along the cortical ribbon to ensure that all cortical
layers were represented in the quantification.
Images were analysed using ImageJ version 1.41 software
(developed by Wayne Rasband NIH, USA). Each image was split
into channels (red, green and blue). The eight-bit blue channel
image was corrected for background illumination using the eight-bit
blue channel of a brightfield image and applying a correction method
adopted from Landini (2006–2010) to produce an evenly illuminated
image. A threshold was then applied to the image to measure the total
amount of specific immunostaining. The same threshold was main-
tained for all images (immunized Alzheimer’s disease and non-immu-
nized control cases) of slides stained together in the same batch. The
percentage of the area examined for each antibody was used to
indicate the corresponding protein load.
Counting of Iba-1-positive microglia and MSR-A-positive microglial
clusters was performed in 30 fields of each of the three brain areas at
magnification 20, aided by an ocular morphometric grid inserted into
one of the eyepieces. The rationale for the additional quantification of
Iba-1 and MSR-A was based on the reported detection of all microglia
(resting and activated) with Iba-1 antibody (Streit et al., 2009), and the
marked clustering pattern of the MSR-A immunostaining we observed.
The CD3-positive T lymphocytes were counted in the entire tissue
section of each brain area analysed, at magnification 10, and
expressed as the number of cells per 100 fields. Parenchymal and peri-
vascular T lymphocytes were included in the quantification.
The grading of cerebral amyloid angiopathy was performed as
described by Chalmers et al. (2003). Briefly, amyloid-b42-immunos-
tained sections were examined and assigned a grade ranging from
zero (no amyloid-laden blood vessels) to four (blood vessels having
a heavy deposit of amyloid that also extends into the surrounding
parenchyma). Cortical and leptomeningeal cerebral amyloid angiopa-
thy in the three brain areas was assessed separately and a median
combined grade was calculated for each case.
Haematoxylin and eosin-stained sections of the three brain areas
were examined for cortical microhaemorrhages (i.e. collections of
haemosiderin-laden macrophages) and microvascular lesions (micro-
scopic foci of parenchymal haemorrhage or infarction) which might
influence the microglial status. Entire sections were assessed at mag-
nification 10 and the sum of microhaemorrhages and microvascular
lesions in the three brain areas was used for the subsequent analyses.
The immunostaining and quantification of amyloid-b42 and phospho-
tau in the brains of 10 of the 11 immunized patients with Alzheimer’s
disease and the 28 non-immunized Alzheimer’s disease control subjects
were previously described (Boche et al., 2010). The data set for this study
was augmented by one extra immunized case and re-analysed using the
same image analysis method as for the microglial markers.
Statistical analysis
The data on antigen load (% area immunostained), sum counts of Iba-
1 or CD-3-positive cells, MSR-A-positive clusters, microhaemorrhages/
microvascular lesions, and the cerebral amyloid angiopathy severity for
the three areas were analysed. The continuous outcome variables were
assessed for normality using one-sample Kolmogorov-Smirnoff tests
and through examination of Q-Q plots. In view of the skewed distri-
bution of the data, the non-parametric Mann-Whitney U-test was
used for comparisons between the two groups (non-immunized con-
trol versus immunized Alzheimer’s disease cases), with median values
reported. Similarly, Spearman’s Rank correlation was used to assess
measurements of inflammatory markers in relation to amyloid-b42
and tau load. The data of the three areas combined were analysed
using SPSS 19 software (SPSS, Inc). P-values 50.05 were considered
statistically significant.
Results
Microglial markers
Iba-1
Immunostaining with Iba-1, which has been reported to label all
microglia, active and resting (Streit et al., 2009), revealed micro-
glial cells with both ramified and amoeboid morphology (Fig. 1A
and B), although most cells displayed ramified morphology regard-
less of the Alzheimer’s disease group (non-immunized controls or
immunized Alzheimer’s disease patients). Quantification showed
no significant difference in the Iba-1 load between the immunized
Alzheimer’s disease and non-immunized control cases, although
there was a trend towards less Iba-1 in the immunized group
(Fig. 1C). Similarly, the total number of Iba-1-positive microglial
cells in 90 fields was not significantly different between immunized
Alzheimer’s disease and non-immunized control groups (Fig. 1D).
Macrophage scavenger receptor A
Immunostaining for MSR-A demonstrated microglia, including
their processes, in a pattern consistent with cell surface membrane
expression of this receptor (Fig. 2A and B). A striking feature, not
observed so markedly with the other microglial antibodies, was
clustering of labelled cells, often associated with amyloid plaques,
which prompted us to undertake manual counting of clusters in
addition to the quantification of the total antigen load. The total
Table 2 Details of microglial markers used
Antibody Associated function or marker of
Iba-1 (ionized calcium-binding adaptor molecule 1) Resting and activated microglia/macrophages, upregulated during activation (Imai et al.,
1996; Ahmed et al., 2007; Streit et al., 2009)
CD64 (Fc RI) High affinity receptor for human IgG, main role in mounting an immune response
(Ravetch and Bolland, 2001; Nimmerjahn and Ravetch, 2006)
CD32 (Fc RII) Low affinity receptor for human IgG, phagocytosis of immune complexes (Ravetch and
Bolland, 2001; Nimmerjahn and Ravetch, 2006)
MSR-A Lipoprotein receptor involved in direct ligand recognition, including that of amyloid-b
(El Khoury et al., 1996)
CD68 Activated/phagocytic macrophages/microglia (Rabinowitz and Gordon, 1989, 1991;
Zotova et al., 2011)
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MSR-A load was significantly lower in the immunized Alzheimer’s
disease (0.01%) than the non-immunized control group (0.10%,
P50.001, Fig. 2C). Similarly, the sum number of MSR-A-positive
clusters was also significantly lower (immunized Alzheimer’s dis-
ease = 22 compared with non-immunized controls = 70,
P50.001, Fig. 2D).
Fc receptor I (CD64)
Antibody to CD64 strongly labelled microglial cells, including their
processes, consistent with the expected pattern for a cell surface
membrane receptor (Fig. 3A and B). The CD64 load was significantly
lower in the immunized Alzheimer’s disease (0.36%) than the non-
immunized control group (0.82%, P = 0.001, Fig. 3C). The CD64
load was several-fold higher than any of the other microglial anti-
gens. In both immunized and non-immunized Alzheimer’s disease
cases the CD64 load was 10 times that obtained for Iba-1, which
has been reported to be expressed by all microglia.
Fc receptor II (CD32)
Immunostaining for CD32 demonstrated microglial cells, although
the cell processes were less strongly defined than with CD64 anti-
body (Fig. 3D and E). The CD32 load was also significantly lower
in the immunized Alzheimer’s disease (0.02%) than the non-
immunized control group (0.04%, P = 0.002, Fig. 3F).
CD68
CD68 was distributed in an intracytoplasmic dot-like pattern con-
sistent with the labelling of lysosomes within microglia, as previ-
ously shown (Zotova et al., 2011) (Fig. 3G and H). The CD68 load
was lower in the immunized (0.02%) than the non-immunized
group (0.05%, P = 0.018, Fig. 3I).
Amyloid-b42 and phospho-tau load
As previously described (Boche et al., 2010), the amyloid-b42 load
was 82% lower in the immunized (0.72%) than the non-immu-
nized Alzheimer’s disease cases (4.06%; P50.001, Fig. 4),
reflecting the removal of amyloid-b as a consequence of amyl-
oid-b immunization. The phospho-tau load was 40% lower in
the immunized (0.46%) than the non-immunized group (0.77%,
P = 0.034, Fig. 4), reflecting a reduction of phospho-tau mainly in
neuronal processes (Boche et al., 2010).
Correlations between microglial
markers and amyloid-b42 and
phospho-tau pathology
Correlations between the microglial antigen load and amyloid-b42
and phospho-tau load were examined in the non-immunized con-
trol and immunized Alzheimer’s disease groups (Tables 3 and 4).
Figure 1 Illustrations of immunostaining for microglial Iba-1 in non-immunized control (cAD) and immunized Alzheimer’s disease (iAD)
cases (A and B), with inset of higher magnification. Quantification results of Iba-1 protein load (C) and the number of Iba-1-positive cells
(D) expressed as scatter plots with lines indicating median values, and Mann-Whitney P-values included. Scale bars = 100mm;
insets = 10 mm.
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Correlations with amyloid-b42
Inverse correlations were observed between the amyloid-b42 load
and two microglial markers in the non-immunized control group:
Iba-1, both the load (Spearman’s  = 0.6, P = 0.001, Fig. 5A)
and the number of cells (Spearman’s  = 0.4, P = 0.026,
Fig. 5B), and the CD32 load (Fc receptor II, Spearman’s
 = 0.6, P50.001, Fig. 5C). Within the immunized
Alzheimer’s disease group, a positive correlation was noted
between the amyloid-b42 load and the number of MSR-A-positive
clusters (Spearman’s  = 0.7, P = 0.024, Fig. 5D). No other correl-
ations between microglial markers and amyloid-b42 load were
observed within the immunized Alzheimer’s disease and non-
immunized control groups (Tables 3 and 4).
Correlations with tau
Correlations were observed between the phospho-tau load and all of
the microglial markers in the non-immunized control group (Fig. 6
and Table 3): Iba-1 load (Spearman’s  = 0.4, P = 0.046, Fig. 6A),
Fc receptor II load (Spearman’s  = 0.4, P = 0.032, Fig. 6B), MSR-A
load (Spearman’s  = 0.4, P = 0.045, Fig. 6C), Fc receptor I load
(Spearman’s  = 0.5, P = 0.010, Fig. 6D), and CD68 load
(Spearman’s  = 0.4, P = 0.036, Fig. 6E). No correlations between
microglial markers and phospho-tau load were observed within the
immunized group (Table 4). The number of Iba-1-positive cells and
MSR-A-positive clusters did not correlate with the phospho-tau load
in either of the Alzheimer’s disease groups (Tables 3 and 4).
Immunoglobulin G
Human IgG was detected in amyloid-b plaques, on microglia
surrounding plaques, and within neurons (often adjacent to
plaques), in both immunized Alzheimer’s disease and non-immu-
nized control cases (Fig. 7A–F). It should be noted, however, that
extensive areas of cortex did not contain immunodetectable IgG,
even where abundant plaques were present. Some cortical and
meningeal blood vessels immunopositive for IgG were also
noted, particularly those with amyloid-b in their walls (i.e. with
cerebral amyloid angiopathy; Fig. 7D and E). Quantification of the
IgG load showed no significant difference between the immunized
Alzheimer’s disease and non-immunized control groups (Fig. 7G).
A correlation between the IgG load and the phospho-tau load was
noted within the non-immunized controls (Spearman’s  = 0.4,
P = 0.030, Fig. 7H, Table 3), but not the immunized Alzheimer’s
disease group (Table 4). In addition, within the non-immunized
control group the IgG load correlated with the load of all micro-
glial antigens examined (Table 3): Iba-1 (Spearman’s  = 0.4,
P = 0.036, Fig. 8A), Fc receptor II (CD32) load (Spearman’s
Figure 2 Illustrations of immunostaining for microglial MSR-A in non-immunized control (cAD) and immunized Alzheimer’s disease (iAD)
cases (A and B), with inset of higher magnification. Quantification results of MSR-A protein load (C) and the number of MSR-A-positive
clusters (D) expressed as scatter plots with lines indicating median values, and Mann-Whitney P-values included. Scale bars = 100mm;
inset = 10mm.
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 = 0.5, P = 0.003, Fig. 8B), MSR-A load (Spearman’s  = 0.6,
P = 0.001, Fig. 8C), Fc receptor I (CD64) load (Spearman’s
 = 0.7, P50.001, Fig. 8D), and CD68 load (Spearman’s
 = 0.7, P = 0.001, Fig. 8E). Within the immunized Alzheimer’s
disease group, similar trends between the IgG load and microglial
markers MSR-A, CD32, and CD64 were observed, but not with
Iba-1 or CD68 (Table 4). No correlation was observed between
the IgG load and the amyloid-b42 load in either of the Alzheimer’s
disease groups (Tables 3 and 4).
Complement C1q
Antibody to the complement element C1q labelled neurons,
amyloid plaques, glia, and occasional blood vessels (Fig. 9A–D),
similarly to anti-IgG antibody. Quantification of C1q also showed
no difference between the immunized Alzheimer’s disease and
non-immunized control groups (Fig. 9E). Within the non-immu-
nized control group, the C1q load correlated only with the phos-
pho-tau load (Spearman’s  = 0.6, P = 0.003, Fig. 9F and Table 3),
whereas in the immunized group, only an inverse correlation be-
tween the C1q load and the amyloid-b42 load was noted
(Spearman’s  = -0.6, P = 0.047, Fig. 9G and Table 4). As for
IgG, the C1q load correlated with the load of all microglial anti-
gens examined within the non-immunized control group (Table 3):
Iba-1 (Spearman’s  = 0.5, P = 0.017, Fig. 10A), CD68
(Spearman’s  = 0.5, P = 0.012, Fig. 10B), CD64 (FcRI,
Spearman’s  = 0.6, P = 0.001, Fig. 10C), CD32 (FcRII,
Spearman’s  = 0.7, P50.001, Fig. 10D), and MSR-A
(Spearman’s  = 0.4, P = 0.036, Fig. 10E). No such correlations
were observed in the immunized Alzheimer’s disease group
(Table 4). Correlations between the C1q load and the IgG load
were found in both the non-immunized control group (Spearman’s
 = 0.7, P50.001, Table 3) and the immunized Alzheimer’s dis-
ease group (Spearman’s  = 0.6, P = 0.035, Table 4).
CD3-positive T lymphocytes
The number of CD3-positive T lymphocytes did not differ signifi-
cantly between the immunized and non-immunized groups
(Fig. 11A). Parenchymal (Fig. 11E) and perivascular (Fig. 11F) T
lymphocytes were included in the quantification. A correlation be-
tween the number of CD3-positive cells and the IgG load was
Figure 3 Illustrations of immunostaining for microglial markers in non-immunized control (cAD) and immunized Alzheimer’s disease (iAD)
cases using antibody against: CD64 (Fc RI) (A and B), CD32 (Fc RII) (D and E), and CD68 (G and H) with inset of higher magnification.
Quantification results of protein load for each microglial marker is expressed as scatter plots with lines indicating median values, and
Mann-Whitney P-values included (C, F and I). Scale bars = 100mm; insets = 10mm.
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observed in both the non-immunized controls (Spearman’s
 = 0.4, P = 0.030, Fig. 11C and Table 3) and immunized
Alzheimer’s disease groups (Spearman’s  = 0.8, P = 0.007,
Fig. 11D and Table 4). The number of CD3-positive T cells corre-
lated with the phospho-tau load within the non-immunized
controls (Spearman’s  = 0.4, P = 0.026, Fig. 11B and Table 3)
but not the immunized Alzheimer’s disease group (Table 4). No
relationships between the CD3 data and any of the microglial
markers, amyloid-b42, or complement C1q were noted in either
of the Alzheimer’s disease groups (Tables 3 and 4).
Cerebral amyloid angiopathy
The assessment of cerebral amyloid angiopathy in the cerebral
cortex and leptomeninges demonstrated more severe cerebral
amyloid angiopathy in the immunized Alzheimer’s disease
(median score = 2.0) than the non-immunized control group
(median score = 1.0, P = 0.044), in accordance with previously re-
ported findings (Boche et al., 2008). However, no relationships
were observed between the cerebral amyloid angiopathy severity
and the microglial markers, amyloid-b42 load, phospho-tau load or
any other parameters investigated in this study.
Microhaemorrhages and microvascular
lesions
The assessment of the haematoxylin and eosin-stained sections
for the number of microhaemorrhages and microvascular lesions
did not reveal any significant differences between the immunized,
and the non-immunized group. No relationships were noted
between the number of microhaemorrhages and microvascular
lesions and the level of microglial markers, amyloid-b42 load, phos-
pho-tau load or any other parameters assessed in the two groups.
Discussion
Microglial activity is closely linked to the development of
Alzheimer’s disease, but the precise role of microglia in disease
pathogenesis and the response to amyloid-b immunization is
Table 3 Results of correlation analyses within non-immunized Alzheimer’s disease control group – Spearman’s  and
P-values
cAD Phospho-tau
load
CD68
load
CD64
load
CD32
load
MSR
load
MSR
clusters
Iba-1
load
Iba-1 +
cells
IgG
load
C1q
load
CD3+
cells
Amyloid-b42
load
 = 0.2  = 0.3  = 0.1  = 0.6  = 0.2  = 0.1  = 0.6  = 0.4  = 0.2  = 0.2  = 0.1
P = 0.428 P = 0.091 P = 0.477 P_ 0.001 P = 0.438 P = 0.660 P = 0.001 P = 0.026 P = 0.370 P = 0.258 P = 0.553
Phospho-tau
load
 = 0.4  = 0.5  = 0.4  = 0.4 5 0.1  = 0.4  = 0.3  = 0.4  = 0.6  = 0.4
P = 0.036 P = 0.010 P = 0.032 P = 0.045 P = 0.936 P = 0.046 P = 0.151 P = 0.030 P = 0.003 P = 0.026
CD68 load  = 0.7  = 0.7  = 0.6  = 0.2  = 0.5  = 0.1  = 0.7  = 0.5  = 0.2
P_ 0.001 P_ 0.001 P_ 0.001 P = 0.441 P = 0.004 P = 0.586 P_ 0.001 P = 0.012 P = 0.244
CD64 load  = 0.6  = 0.5  = 0.2  = 0.5  = 0.2  = 0.7  = 0.6  = 0.3
P = 0.001 P = 0.003 P = 0.387 P = 0.007 P = 0.444 P_ 0.001 P = 0.001 P = 0.095
CD32 load  = 0.4 5 0.1  = 0.7  = 0.5  = 0.5  = 0.7  = 0.1
P = 0.052 P = 0.912 P_ 0.001 P = 0.011 P = 0.003 P_ 0.001 P = 0.446
MSR load  = 0.5  = 0.4  = 0.1  = 0.6  = 0.4 5 0.1
P = 0.002 P = 0.054 P = 0.725 P = 0.001 P = 0.036 P = 0.899
MSR clusters  = 0.1  = 0.1  = 0.1 5 0.1  = 0.2
P = 0.750 P = 0.524 P = 0.459 P = 0.801 P = 0.208
Iba-1 load  = 0.7  = 0.4  = 0.5 5 0.1
P_ 0.001 P = 0.036 P_ 0.017 P = 0.818
Iba-1 + cells  = 0.1  = 0.3  = 0.1
P = 0.701 P = 0.165 P = 0.750
IgG load  = 0.7  = 0.4
P_ 0.001 P = 0.030
C1q load  = 0.3
P = 0.141
cAD = non-immunized Alzheimer’s disease control.
Significant correlations are highlighted in bold.
Figure 4 Results of the amyloid-b42 and phospho-tau
quantification summarized in a scatter plot with lines indicating
median values and Mann-Whitney P-values included.
cAD = non-immunized Alzheimer’s disease controls;
iAD = immunized Alzheimer’s disease cases.
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unclear. The poor cognitive outcome of patients in the AN1792
clinical trial suggested that clearance of amyloid-b plaques alone is
not sufficient to halt the progression of dementia (Holmes et al.,
2008), raising the possibility that persistent microglial activation
results in continuing neurodegeneration. In the current study, we
have investigated microglial receptors involved in direct and anti-
body-mediated ligand recognition and clearance in human post-
mortem Alzheimer’s disease tissue, their relation to amyloid-b and
phospho-tau pathology and other inflammatory processes, and
how these relationships are altered after active amyloid-b42
immunization.
Microglial markers and pathological
features of Alzheimer’s disease,
amyloid-b42 and tau
Consistent with previously reported findings, we observed signifi-
cantly lower amyloid-b42 and phospho-tau loads after amyloid-b
immunization (Boche et al., 2010). In conjunction with these
alterations in the pathology of the disease, we observed significant
changes in microglial receptors and markers of the CNS innate
immune response.
Correlations between amyloid-b42 and
microglial markers
With respect to amyloid-b42, inverse correlations were observed with
Iba-1 and Fc receptor II in non-immunized Alzheimer’s disease only.
Iba-1 is expressed constitutively by microglia in the brain, with
increased expression upon activation (Imai et al., 1996; Imai and
Kohsaka, 2002). It was proposed that Iba-1 is involved in cytoskeletal
reorganization, membrane ruffling and actin cross-linking in micro-
glia, necessary for phagocytosis (Ohsawa et al., 2000; Sasaki et al.,
2001; Kanazawa et al., 2002). The Fc receptors expressed by micro-
glia are important players in phagocytosis, transport and clearance of
antibodies and immune complexes from the brain, and antibody-
dependent cell-mediated cytotoxicity (Ulvestad et al., 1994a;
Deane et al., 2009). The ability of anti-amyloid-b antibodies to
cross the blood–brain barrier has been reported in animal models
(Bard et al., 2000; Deane et al., 2005). Anti-amyloid-b autoantibo-
dies were detected in the plasma of patients with Alzheimer’s disease
(Hyman et al., 2001), consistent with the detection of Fc receptors
in the non-immunized Alzheimer’s disease brains. One explanation
for the inverse correlations between amyloid-b and the microglial
Iba-1 and Fc receptor II may be that in Alzheimer’s disease, the
expression of these receptors limits the accumulation of amyloid.
Alternatively, the inverse relationship could reflect a mechanism
whereby amyloid-b aggregation and, presumably, amyloid-b
immune complexes, downregulate microglia as a means of minimiz-
ing neuronal damage in the context of a prolonged inflammatory
reaction. It was suggested that activation of Fc receptors leads to
increased levels of intracellular Ca2 + (Ravetch and Kinet, 1991), pos-
sibly indicating a link with the calcium adapter protein Iba-1.
Immunization alters the relationship between amyloid-b42 and
these microglial receptors. This may contribute to a change in
microglial function that facilitates amyloid-b clearance, as sug-
gested by the correlation between the cell surface scavenger
receptor MSR-A-positive clusters and amyloid-b42 in immunized
Alzheimer’s disease cases. MSR-A was reported to be involved
in the activation of microglia for uptake of extracellular matter,
including amyloid (Christie et al., 1996). We observed no relation-
ship between microglia and vascular amyloid-b (cerebral amyloid
Table 4 Results of correlation analyses within the immunized Alzheimer’s disease group – Spearman’s  and P-values
iAD Phospho-tau
load
CD68
load
CD64
load
CD32
load
MSR
load
MSR
clusters
Iba-1
load
Iba-1+
cells
IgG
load
C1q
load
CD3+
cells
Amyloid-b42
load
 = 0.4  = 0.2  = 0.5  = 0.3  = 0.4  = 0.7  = 0.1  = 0.2  = 0.2  = 0.6  = 0.2
P = 0.212 P = 0.484 P = 0.151 P = 0.326 P = 0.272 P = 0.024 P = 0.689 P = 0.650 P = 0.537 P = 0.047 P = 0.555
Phospho-tau
load
 = 0.2  = 0.2  = 0.5  = 0.4  = 0.5  = 0.2 5 0.1  = 0.1  = 0.2  = 0.3
P = 0.484 P = 0.574 P = 0.110 P = 0.201 P = 0.098 P = 0.612 P = 0.915 P = 0.811 P = 0.502 P = 0.433
CD68 load  = 0.8  = 0.4  = 0.6  = 0.3  = 0.1  = 0.6  = 0.5  = 0.3  = 0.5
P = 0.004 P = 0.180 P = 0.060 P = 0.377 P = 0.770 P = 0.051 P = 0.177 P = 0.450 P = 0.125
CD64 load  = 0.5  = 0.7  = 0.4  = 0.2  = 0.2  = 0.6  = 0.3  = 0.5
P = 0.102 P = 0.016 P = 0.174 P = 0.593 P = 0.593 P = 0.077 P = 0.417 P = 0.170
CD32 load  = 0.6  = 0.5  = 0.5 5 0.1  = 0.6  = 0.1  = 0.5
P = 0.071 P = 0.141 P = 0.096 P = 0.979 P = 0.066 P = 0.770 P = 0.110
MSR load  = 0.4  = 0.6 5 0.1  = 0.6  = 0.3  = 0.4
P = 0.264 P = 0.051 P = 0.915 P = 0.066 P = 0.417 P = 0.201
MSR clusters  = 0.4  = 0.2  = 0.1  = 0.1  = 0.1
P = 0.194 P = 0.492 P = 0.709 P = 0.852 P = 0.884
Iba-1 load  = 0.6  = 0.4  = 0.3  = 0.3
P = 0.056 P = 0.285 P = 0.340 P = 0.340
Iba-1 + cells  = 0.3  = 0.1  = 0.3
P = 0.450 P = 0.750 P = 0.370
IgG load  = 0.6  = 0.8
P = 0.035 P = 0.007
C1q load  = 0.6
P = 0.077
iAD = immunized Alzheimer’s disease.
Significant correlations are highlighted in bold.
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angiopathy) in Alzheimer’s disease brains. Even after the immun-
ization, which results in a transient increase in cerebral amyloid
angiopathy (Boche et al., 2008), no association between microglial
markers and the severity of cerebral amyloid angiopathy was
noted. Similarly, microglial activity was not related to the
number of microhaemorrhages and microvascular lesions, al-
though the lack of apparent relationship may simply reflect the
relatively infrequent occurrence of these lesions in the present
cohort.
Correlation between tau and microglial markers
In the non-immunized Alzheimer’s disease cases, phospho-tau
load, but not amyloid-b, correlated with the levels of all of the
microglial markers assessed. There is evidence for a connection
between microglial activation and tau pathology in Alzheimer’s
disease and other tauopathies (DiPatre and Gelman, 1997;
Ishizawa and Dickson, 2001; Streit et al., 2009; Serrano-Pozo
et al., 2011). Chronic microglial activation resulting in the release
of pro-inflammatory cytokines (e.g. IL-1, IL-1b and TNF) and
other molecules (e.g. quinolinic acid) may cause tau hyperpho-
sphorylation (Iqbal and Grundke-Iqbal, 2002; Li et al., 2003), sug-
gesting that microglia may contribute to the ongoing
neurodegeneration (Serrano-Pozo et al., 2011). Conversely, micro-
glial activity may be a response to the synaptic loss associated with
tau pathology (Iqbal and Grundke-Iqbal, 2002), supporting the
concept that microglia are losing their protective capacities with
ageing (Streit et al., 2009).
Our observations of correlations between microglia and tau, and
between microglia and amyloid-b, but not between tau and amyl-
oid-b in Alzheimer’s disease, suggest that microglia may play a
pivotal role in Alzheimer’s disease. We did not observe any rela-
tion between the tau pathology and microglial markers in the
immunized Alzheimer’s disease group, in keeping with a change
in the microglial profile after immunization focusing on amyloid-b
clearance (Zotova et al., 2011). The exact pathway and sequence
of events that involve microglia, amyloid-b and phospho-tau, in
the pathogenesis of Alzheimer’s disease are still not deciphered.
Microglial activation may represent a response that is aimed at
limiting amyloid-b deposition (inverse correlation between some
microglial markers and amyloid-b42), as observed by in vivo ima-
ging of transgenic mice (Bolmont et al., 2008) but that causes
secondary neuronal damage (direct correlation between all micro-
glial markers and phospho-tau). Alternatively, microglial activation
may be triggered by the neuronal damage in Alzheimer’s disease,
Figure 5 Correlation plots between microglial and amyloid-b42 (21F12) within non-immunized control (cAD) (A–C) and immunized
Alzheimer’s disease (iAD) groups (D) with linear regression lines and Spearman’s  and P-values included. Within the non-immunized
control group, the amyloid-b42 load inversely correlated with Iba-1 load (A), the number of Iba-1-positive cells (B), and CD32 (Fc RII)
load (C). Within the immunized Alzheimer’s disease group, the amyloid-b42 load correlated with the number of MSR-A-positive microglial
clusters (D).
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with amyloid-b deposition serving as an attempt to control the
inflammation (Soscia et al., 2010). The possibility that plaque-
associated amyloid-b is not directly involved in neurodegeneration
in sporadic Alzheimer’s disease is consistent with our observations
of continued decline in cognitive function, despite the removal of
amyloid-b plaques by immunotherapy (Holmes et al., 2008).
Immunoglobulin G
We quantified IgG to assess the extent of opsonization of amyl-
oid-b plaques before and after immunization, but found no
significant difference in total load of IgG within the cortex. This
is despite evidence that anti-amyloid-b antibodies persist for many
years in the blood of patients immunized with AN1972 (Holmes
et al., 2008). It should be noted that the immunohistochemistry
did not differentiate between host-generated antibodies of differ-
ent specificities (e.g. anti-amyloid-b) that might be present in the
brain. It is possible that an increase in amyloid-b-specific antibody
level and immune complex formation within the brain takes place
in Alzheimer’s disease brain immediately after the treatment, as
observed in animal studies using passive immunization (Bard et al.,
2000). If so, our observations of lower levels of Fc receptors I
Figure 6 Correlation plots between microglial and phospho-tau (AT8) within the non-immunized control group with linear regression
lines and Spearman’s  and P-values included. Phospho-tau load correlated with Iba-1 load (A), CD32 (Fc RII) load (B), MSR-A load
(C), CD64 (Fc RI) load (D), and CD68 load (E).
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and II in immunized cases by the time of autopsy suggest that the
deployment of these receptors for the clearance of amyloid-b is
followed by their downregulation.
There was a correlation between IgG and phospho-tau within
the non-immunized but not the immunized Alzheimer’s disease
group. A link has been proposed between changes in brain–
blood barrier permeability in Alzheimer’s disease and the influx
and localization of IgG within neurons, leading to tau-mediated
reorganization of neuronal microtubules (Bouras et al., 2005). Our
findings would be consistent with the presence of IgG in the brain
influencing the extent of the tau pathology. This is in keeping with
the strong correlations between the amount of IgG and the levels
of all microglial receptors, and between these receptors and phos-
pho-tau, as discussed above. Similarly, T cell numbers correlated
with the IgG load and phospho-tau pathology in the non-immu-
nized Alzheimer’s disease group, supporting the involvement of
humoral immunity, in addition to cellular immunity in the patho-
genesis of Alzheimer’s disease (Bouras et al., 2005). Immunization
against amyloid-b42 seems to alter these relationships, perhaps
reflecting alteration in the type of IgG present in the brain follow-
ing the treatment. However, the relationship between T cells and
IgG was still present in the immunized cases and at a stronger
level. Consistent with this observation, the ability of microglia-
mediated antibody-dependent phagocytosis involving Fc
receptors to stimulate T cells has been demonstrated in vitro
(Ulvestad et al., 1994b).
C1q
Although no changes were observed in the total C1q load be-
tween both groups, the differences in correlations between C1q
and microglial markers, and C1q and amyloid-b42/tau support a
role for C1q in Alzheimer’s disease pathogenesis and immuniza-
tion-related changes. Consistent with the recent identification of
complement gene variation as risk factor for Alzheimer’s disease
(Lambert et al., 2009), and the suggested ability of C1q to acti-
vate microglial cells (Veerhuis et al., 2003), C1q correlated with all
microglial markers in the non-immunized Alzheimer’s disease
group. The findings are also in accordance with the in vitro dem-
onstrations of microglial C1q-mediated Fc receptor-dependent
phagocytosis of immune complexes (Webster et al., 2000,
2001). In the non-immunized group there was also a relationship
between C1q and phospho-tau, supporting a view that C1q ex-
pression is related to the degeneration of neurons in Alzheimer’s
disease (Fonseca et al., 2004; D’Andrea, 2005). The ability of tau
to activate complement through C1q was previously demonstrated
in vitro and in situ (Shen et al., 2001). In the immunized group,
this relationship was no longer present. Instead, an inverse
Figure 7 Illustrations of IgG immunostaining: amyloid-b plaque (A); amyloid-b core (B); glial cell (C); IgG within blood vessel wall
(D) capillary angiopathy (E); and neuron (F). Scale bar = 10 mm. (G) Quantification results of IgG load in non-immunized controls and
immunized Alzheimer’s disease cases expressed as scatter plot with lines indicating median values, and Mann-Whitney P-values included.
(H) Correlation plot between the IgG load and phospho-tau (AT8) load within the non-immunized control group with linear regression line
and Spearman’s  and P-values included. cAD = non-immunized Alzheimer’s disease controls; iAD = immunized Alzheimer’s disease cases.
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relationship between amyloid-b42 and C1q was observed, suggest-
ing a different role for C1q after immunization, perhaps related to
the clearance of amyloid-b, as increased uptake of C1q-coated
fibrillar amyloid-b particles and immune complexes by rodent
microglia in vitro has been reported (Brazil et al., 2000; Webster
et al., 2001). Overall, our observations indicate that C1q is likely
to be a mediator in the microglia-amyloid-b-tau network in
Alzheimer’s disease and that its role in this network is altered by
immunization.
Effect of immunization on microglial
receptors, cell number and distribution
Human data on the detailed microglial profile in chronic neurode-
generation and in response to stimulation of the immune system
are scarce. Animal studies suggest that induction of an immune
response in the brain leads to acutely elevated levels of microglial
receptors (Herber et al., 2006, 2007, Malm et al., 2008, Ryu
et al., 2009), and alterations in an inflammatory gene profile
Figure 8 Correlation between microglial markers and IgG load in non-immunized controls with linear regression lines and Spearman’s
 and P-values included. Correlations were observed between the IgG load and Iba-1 load (A), CD32 (Fc RII) load (B), MSR-A load
(C), CD64 (Fc RI) load (D), and CD68 load (E).
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towards classical activation associated with reduced brain amyloid-
b levels (Wilcock et al., 2011).
Our quantitative analysis of the microglial markers MSR-A,
CD64, CD32 and CD68 revealed significantly lower levels of
these receptors in immunized Alzheimer’s disease cases, perhaps
surprisingly suggesting downregulation of microglial activity after
immunization, at least by the time of post-mortem examination,
which in almost all cases was several years after treatment. In the
immunized group, we observed an 89% lower load of the scav-
enger receptor MSR-A and a 68% lower number of MSR-A-posi-
tive clusters, consistent with the degree of plaque removal seen in
these cases. The Fc receptors I and II, expected to be involved in
the CNS innate immune response to immunotherapy, were 56%
and 66% lower after immunization. The marker of intracellular
microglial lysosomes, CD68, was also 60% lower in the immu-
nized group. Although in our previous study we reported a
higher load of CD68 in immunized cases (Zotova et al., 2011),
the current non-immunized Alzheimer’s disease cohort is larger
and better matched for age, gender, duration of dementia and
APOE genotype to the immunized group, which includes some
additional cases with longer post-immunization times. Our current
finding of an overall lower CD68 load in the immunized cases is in
accordance with our findings for all other microglial markers, and
highlights the necessity of using large and well-matched control
cohorts for studies of human tissue (Boche et al., 2013). It should
be noted that the findings on analysis of post-mortem tissue sev-
eral years following the immunization may not necessarily reflect
those immediately after receiving the treatment, and instead rep-
resent the late effects after plaque removal has occurred. Although
all of the markers of microglial activation were lower after immun-
ization, we detected no difference in Iba-1 load or the number of
Iba-1-positive cells between the groups. Iba-1 antibody is reported
to label all microglia, whether resting or active (Streit et al., 2009).
In accordance with this we expected, but did not observe, a higher
Iba-1 load than that of the other microglial markers. Simard et al.
(2006) showed that blood-derived monocytes can be recruited
into the brain of transgenic mice and differentiate into microglia-
like cells, which are more efficient at clearing amyloid-b plaques.
The lack of increase in total microglia number after the immun-
ization provides no evidence for immunization-induced recruit-
ment of monocytes from the periphery or in situ proliferation of
microglia.
Figure 9 Illustrations of C1q immunostaining demonstrating positively stained neurons (filled triangle, A), amyloid-b plaques (hash
symbol, B and C); glial cell (asterisk, B and D), blood vessels ( , C), and other cells (possibly astrocytes, 5, D). Scale bar = 50 mm.
(E) Quantification results of C1q load in non-immunized controls and immunized Alzheimer’s disease cases expressed as scatter plot with
lines indicating median values, and Mann-Whitney P-values included. (F) Correlation plot between the C1q load and phospho-tau (AT8)
load within the non-immunized control group with linear regression line and Spearman’s  and P-values included. (G) Correlation plot
between the C1q load and amyloid-b42 load within the immunized Alzheimer’s disease group with linear regression line and Spearman’s
 and P-values included.
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Our observation of a strong clustering pattern of MSR-A-posi-
tive microglia is in accordance with other studies that looked at
expression of macrophage scavenger receptors in Alzheimer’s dis-
ease and non-demented brains (Christie et al., 1996; Honda et al.,
1998) suggesting that these clusters are related to amyloid-b pla-
ques and consistent with the function of MSR-A (Chung et al.,
2001). We previously reported clustering and co-localization of
microglial markers HLA-DR and CD68 around amyloid-b plaques
(Zotova et al., 2011). We did not observe any obvious amyloid-b-
related clustering of cells expressing Fc receptors, in keeping with
a previous report that these cells are distributed throughout the
cortex of normal and Alzheimer’s disease brains (Peress et al.,
1993). The variability in the distribution of microglial markers
that we observed in human disease suggest that microglia may
be present in different functional states in the same brain in
Alzheimer’s disease, with further alterations in microglial activation
and function following amyloid-b immunization. The distinct dis-
tribution of MSR-A immunostaining may be explained by the se-
lective immobilization of the MSR-A-positive cells when they
encounter plaques. Indeed, in vitro studies using murine microglial
cells showed that the murine homologue of MSR-A was the first
receptor to engage in phagocytosis of amyloid-b fibrils (El Khoury
et al., 1996; Paresce et al., 1996), resulting in immobilization of
microglia and release of neurotoxic cytokines and reactive oxygen
species (El Khoury et al., 1996; Husemann et al., 2002). Similar
observations were made on cultured human microglia from
Figure 10 Correlation between microglial markers and C1q load in non-immunized controls with linear regression lines and Spearman’s
 and P-values included. Correlations were observed between the C1q load and Iba-1 load (A), CD68 load (B), CD64 (Fc RI) load
(C), CD32 (Fc RII) load (D), and MSR-A load (E).
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Alzheimer’s disease and non-demented cases (Lue and Walker,
2002).
Together, our data on the levels of microglial receptors involved
in antigen recognition and uptake suggest that, in the long term,
immunotherapy has a downregulating effect on the expression of
these receptors, while keeping the overall number of microglia
unaltered. These findings are counter to the observations in
animal models, challenging the fidelity of animal models as
mimics of the complexity of the human disease. Importantly, the
time-course also differed: in the experimental models the response
was typically studied after a matter of days or few months,
whereas we are investigating the brains of patients with
Alzheimer’s disease almost all of whom were studied several
years following immunization. However, individual data on micro-
glial markers from the immunized Alzheimer’s disease cases exam-
ined shortly after the immunization (e.g. Patient iAD2, 4 months
following the treatment), was similar to the rest of the cases
within the immunized Alzheimer’s disease group, despite signs of
Figure 11 Quantification results of CD3-positive T cells in non-immunized controls and immunized Alzheimer’s disease cases expressed
as scatter plot with lines indicating median values, and Mann-Whitney P-values included (A). Correlation plots between the number of
CD3-positive T cells and the phospho-tau (AT8) load within the non-immunized control group with linear regression line and Spearman’s
 and P-values included (B). Correlation plots between the number of CD3-positive T cells and the IgG load within the non-immunized
control group (C) and the immunized Alzheimer’s disease group (D) with linear regression line and Spearman’s  and P-values included.
Examples of CD3 immunostaining in parenchyma (E) and perivascular (F). Scale bar = 30mm.
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active clearance of amyloid-b plaques (Nicoll et al., 2006; Zotova
et al., 2011). In addition, no correlations were observed between
the inflammatory markers and survival time post-immunization.
The mechanisms of amyloid-b removal may vary according to
the different treatment protocols in clinical trials, of which there
are currently 440 in progress worldwide (Menendez-Gonzalez
et al., 2011). We previously found elevated microglial phagocyt-
osis in patients with Alzheimer’s disease (Zotova et al., 2011), with
evidence of amyloid-b within microglia (Nicoll et al., 2006), but
also elevated soluble amyloid-b (Maarouf et al., 2010) and
increased severity of cerebral amyloid angiopathy, interpreted as
a reflection of enhanced exit of soluble amyloid-b from the brain
by the perivascular pathway (Boche et al., 2008). Although based
on few cases, the data suggested that, once the brain was cleared
of amyloid-b plaques, all these features fell below the level seen in
non-immunized Alzheimer’s disease brain. Our current findings
further confirm that microglial markers of activation and other
inflammatory processes are all reduced following the
immunization.
Conclusion
Overall, our data reveal antigenically and probably functionally dif-
ferent populations of microglia in the Alzheimer’s disease brain: some
are predominantly located in and around plaques (e.g. MSR-A-posi-
tive microglia) and therefore presumably responding in a specific way
to plaque components, whereas others are diffusely distributed
through the cortex, perhaps responding or contributing to neuronal
damage. This reinforces the concept of specific phenotypes of micro-
glia, with different functions as defined in animal studies (Perry et al.,
2010), and confirms its relevance to human neurodegenerative dis-
ease. Interestingly, for the first time in Alzheimer’s disease, a link was
observed between all the inflammatory processes (microglia, IgG and
C1q) and tau, supporting an active role for immune functions in the
pathogenesis of Alzheimer’s disease. The recent genetic data to
emerge from the genome-wide association studies indicates that at
least a component of the inflammation contributes towards disease
pathogenesis and may be amenable to early intervention.
Our findings provide no evidence of a broad-spectrum long-
term increase in microglial activation after immunotherapy despite
the enhanced microglial phagocytosis of plaque-associated amyl-
oid-b. Instead, we suggest that the microglial downregulation is
likely to minimize bystander damage at least in the longer term.
These observations highlight the complex nature of microglial re-
actions and the importance of attempting to assess not just the
presence but also the functional state of microglia. The details
revealed in this study highlight the importance of conducting
neuropathological follow-up as part of clinical trials of new thera-
pies in Alzheimer’s disease.
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